Aptose Biosciences, Inc. (NASDAQ:APTO) (TSE:APS) shares saw unusually-strong trading volume on Tuesday . Approximately 2,034,100 shares changed hands during mid-day trading, an increase of 415% from the previous session’s volume of 394,783 shares.The stock last traded at $2.05 and had previously closed at $1.70.
A number of analysts have recently weighed in on APTO shares. Zacks Investment Research upgraded shares of Aptose Biosciences from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a research note on Monday, August 14th. ValuEngine lowered shares of Aptose Biosciences from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. HC Wainwright upgraded shares of Aptose Biosciences from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $1.00 to $4.00 in a research note on Thursday, September 7th. Finally, Roth Capital reissued a “buy” rating and set a $5.00 price target on shares of Aptose Biosciences in a report on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $5.90.
WARNING: This story was published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://transcriptdaily.com/2017/11/14/aptose-biosciences-inc-apto-sees-strong-trading-volume.html.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.